GLOBAL MILESTONE EVENTS IN CRYOMEDICINE
In 1949, British scientist Polge
Discovered that glycerin could be used as a cryoprotectant to preserve sperm at low temperatures
In 1949, British scientist Polge
Discovered that glycerin could be used as a cryoprotectant to preserve sperm at low temperatures
Glycerin, as the main ingredient of the world’s first cryoprotectant, enabled humans to achieve efficient cryopreservation of semen for the first time, laying a solid technical foundation for human sperm banks built around the world after the 1960s. Currently, nearly 2 million in vitro fertilization and 1 million artificial insemination cases are performed globally each year, curing nearly 80% of infertile patients worldwide and bringing patients the opportunity to welcome new life.
In 1949, British scientist Polge
Discovered that glycerin could be used as a cryoprotectant to preserve sperm at low temperatures
In 1967, the world’s first cryopreserved human
Dr. James Bedford, was preserved at the American Human Cryonics Society (Alcor).
In 1967, the world’s first cryopreserved human
Dr. James Bedford, was preserved at the American Human Cryonics Society (Alcor).
It kicked off the research on cryopreservation and resuscitation of human tissues and organs. At present, there are only 4 institutions in the world that can independently implement human cryopreservation. Shandong Yinfeng Life Science Research Institute in our country is the only institution in Asia that can independently implement human cryopreservation, and completed the first case of human cryopreservation in China in 2017. Currently, 16 volunteers from all over the country have been preserved in our institute. Human preservation and resuscitation research is a future-oriented and challenging frontier life science research project through the joint research of interdisciplinary subjects such as cryobiology, cryomedicine, molecular biology, and clinical medicine.
In 1967, the world’s first cryopreserved human
Dr. James Bedford, was preserved at the American Human Cryonics Society (Alcor).
In 1980, the New York Blood Center’s Rowe
Successfully resuscitated red blood cells that had been preserved at liquid nitrogen temperature for 12 years
In 1980, the New York Blood Center’s Rowe
Successfully resuscitated red blood cells that had been preserved at liquid nitrogen temperature for 12 years
The success of cell cryopreservation and resuscitation has a profound impact on the clinical application of disciplines such as reproductive medicine, immunology, regenerative medicine, etc. Currently, it brings hope of cure to nearly 17.6% of patients with reproductive dysfunction, 20 million cancer patients, and 2 million patients in urgent need of tissue or organ transplantation every year.
In 1980, the New York Blood Center’s Rowe
Successfully resuscitated red blood cells that had been preserved at liquid nitrogen temperature for 12 years
In 1989, Professor Belzer of the University of Wisconsin, USA
Invented the UW cryopreservation solution
In 1989, Professor Belzer of the University of Wisconsin, USA
Invented the UW cryopreservation solution
The invention of the UW preservation solution greatly improved the quality and preservation time of cell and in vitro tissue and organ preservation, and derived tens of thousands of various deep cryoprotectants on this basis, effectively reducing the formation of nearly 70% of ice crystals in cells, tissues, and organs, and prolonging and improving the life and postoperative quality of life of nearly 130,000 organ transplant patients worldwide each year.
In 1989, Professor Belzer of the University of Wisconsin, USA
Invented the UW cryopreservation solution
In 1991, the world’s first mixed cord blood transplant surgery was successfully performed by Chinese medical expert Professor Shen Bojun
(Chief Scientist of Yinfeng Biological Group, Director of Hematopoietic Stem Cell Bank of Cord Blood in Shandong Province)
In 1991, the world’s first mixed cord blood transplant surgery was successfully performed by Chinese medical expert Professor Shen Bojun
(Chief Scientist of Yinfeng Biological Group, Director of Hematopoietic Stem Cell Bank of Cord Blood in Shandong Province)
Since then, the prelude to the treatment of major hematological diseases with umbilical cord blood stem cells has been opened. At present, 7 cord blood banks in the country have a total of 2.62 million cord blood stored, and a total of more than 30,000 patients have been cured by application, accounting for 35% of the total number of applications worldwide. The application of cord blood stem cells has saved tens of thousands of patients whose lives are threatened by hematological diseases.
In 1991, the world’s first mixed cord blood transplant surgery was successfully performed by Chinese medical expert Professor Shen Bojun
(Chief Scientist of Yinfeng Biological Group, Director of Hematopoietic Stem Cell Bank of Cord Blood in Shandong Province)
In 2016, Shandong Yinfeng Life Science Research Institute
Developed the world’s first high-precision low-temperature programmed cooling equipment
In 2016, Shandong Yinfeng Life Science Research Institute
Developed the world’s first high-precision low-temperature programmed cooling equipment
At present, this programmed cooling equipment is the largest in the world, with the widest temperature control range and highest precision. It fills the global technical gap of programmed cooling instruments from room temperature to -196℃ in a continuous curve and solves the demand for large-size cooling instruments for various types of large-volume tissues, organs and human body preservation. It is exported and circulated worldwide, and was exported to Australia in 2021, demonstrating China’s scientific and technological strength in the cryobiological domain.
In 2016, Shandong Yinfeng Life Science Research Institute
Developed the world’s first high-precision low-temperature programmed cooling equipment
In 2017, Shandong Yinfeng Life Science Research Institute
First time applied the minimally invasive dual-channel extracorporeal circulation perfusion technology to human cryopreservation surgery
In 2017, Shandong Yinfeng Life Science Research Institute
First time applied the minimally invasive dual-channel extracorporeal circulation perfusion technology to human cryopreservation surgery
The application of human minimally invasive dual-channel extracorporeal circulation perfusion surgery technology, compared to the traditional need for thoracotomy to perfuse the human body with cryoprotectant, reduces the formation of wounds and ensures that the cryoprotectant can quickly and fully reach all tissues of the body, laying a good technical foundation for future human tissue and organ resuscitation experiments.
In 2017, Shandong Yinfeng Life Science Research Institute
First time applied the minimally invasive dual-channel extracorporeal circulation perfusion technology to human cryopreservation surgery
In 2017, China’s first human body cryopreservation
Successfully completed at Shandong Yinfeng Life Science Research Institute
In 2017, China’s first human body cryopreservation
Successfully completed at Shandong Yinfeng Life Science Research Institute
In 2017, our institute successfully implemented the first case of human cryopreservation in China (also the first case in Asia), making China the third country that can fully implement the full process of human body cryopreservation after the United States and Russia. It marks that the development of China’s cryobiomedical technology is gradually at the forefront of the world.
In 2017, China’s first human body cryopreservation
Successfully completed at Shandong Yinfeng Life Science Research Institute
In 2023, the world’s first vitrified preservation
Nanoheated and rewarmed rat kidney successfully transplanted
In 2023, the world’s first vitrified preservation
Nanoheated and rewarmed rat kidney successfully transplanted
The team of Professor John Bischof of the University of Minnesota (UMN) in the United States successfully transplanted a rat kidney with vitrification preservation and nano-heating rewarming for the first time. The successful implementation of this animal organ rewarming clinical trial provides a scientific basis for clinical practice for the rewarming of human deep cryopreserved organs in the future, and will bring hope of life to nearly 60% of patients in urgent need of organ transplantation worldwide each year
In 2023, the world’s first vitrified preservation
Nanoheated and rewarmed rat kidney successfully transplanted
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
